Prophylactic application of nebulized liposomal amphotericin B in hematologic patients with neutropenia Neutropenia

Onkologie

Volumn 34, Issue 5, 2011, Pages 254-258

  Hullard Pulstinger, Annette ^a   Holler, Ernst ^a   Hahn, Joachim ^a   Andreesen, Reinhard ^a   Krause, Stefan W ^b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Amphotericin; Antibiotic prophylaxis; Antifungal agents; Inhalation; Neutropenia

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DISEASE DURATION; DRUG SCREENING; HUMAN; IMMUNOPROPHYLAXIS; LUNG MYCOSIS; MAJOR CLINICAL STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PYREXIA IDIOPATHICA; STEM CELL TRANSPLANTATION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; FEMALE; HUMANS; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME;

EID: 79957493803     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000327802     Document Type: Article

References (18)

1. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K: Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23-32. (Pubitemid 26289847)
2. Marr KA, Carter RA, Crippa F, Wald A, Corey L: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-917. (Pubitemid 34229758)
3. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Ame S, Fohrer C, Lioure B, Bilger K, Lutun P, Marcellin L, Launoy A, Freys G, Bergerat JP, Herbrecht R: Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008;47:1176-1184.
4. Schwartz S, Behre G, Heinemann V, Wandt H, Schilling E, Arning M, Trittin A, Kern WV, Boenisch O, Bosse D, Lenz K, Ludwig WD, Hiddemann W, Siegert W, Beyer J: Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: Results of a prospective randomized multicenter trial. Blood 1999;93:3654-3661. (Pubitemid 29249811)
5. Griese M, Schams A, Lohmeier KP: Amphotericin B and pulmonary surfactant. Eur J Med Res 1998;3:383-386.
6. Allen SD, Sorensen KN, Nejdl MJ, Durrant C, Proffit RT: Prophylactic efficacy of aerosolized liposomal (ambisome) and non-liposomal (fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 1994;34:1001-1013.
7. Ruijgrok EJ, Vulto AG, Van Etten EW: Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother 2001;48:89-95. (Pubitemid 32684730)
8. Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA, van Etten EW, Vulto AG: Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: Evidence for longterm biological activity. J Pharm Pharmacol 2005; 57:1289-1295. (Pubitemid 41545894)
9. Cicogna CE, White MH, Bernard EM, Ishimura T, Sun M, Tong WP, Armstrong D: Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1997;41:259-261. (Pubitemid 27111015)
10. Purcell IF, Corris PA: Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema. Thorax 1995;50:1321-1323.
11. Palmer SM, Drew RH, Whitehouse JD, Tapson VF, Davis RD, McConnell RR, Kanj SS, Perfect JR: Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation 2001;72:545-548. (Pubitemid 32769650)
12. Altmannsberger P, Holler E, Andreesen R, Krause SW: Amphotericin B deoxycholate: No significant advantage of a 24 h over a 6 h infusion schedule. J Antimicrob Chemother 2007;60:180-182. (Pubitemid 47073302)
13. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002;34:7-14. (Pubitemid 33152659)
14. Subira M, Martino R, Rovira M, Vazquez L, Serrano D, De La Camara R: Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. Ann Hematol 2003;82:80-82. (Pubitemid 36700979)
15. Borlenghi E, Cattaneo C, Capucci MA, Pan A, Quaresmini G, Franco F, Grazioli L, Carosi GP, Rossi G: Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates. Ann Hematol 2007;86:205-210. (Pubitemid 46195993)
16. Schiel X, Link H, Maschmeyer G, Glass B, Cornely OA, Buchheidt D, Wilhelm M, Silling G, Helmerking M, Hiddemann W, Ostermann H, Hentrich M: A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. Infection 2006;34:118-126. (Pubitemid 43979659)
17. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348-359. (Pubitemid 46148777)
18. Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, Ruijgrok EJ, Lowenberg B, Vulto A, Lugtenburg PJ, de Marie S: Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized, placebo-controlled trial. Clin Infect Dis 2008;46:1401-1408. (Pubitemid 351589940)